Bankole A. Johnson, M.D., Chief Medical Officer of Adial Pharmaceuticals Delivers Keynote Lecture; Receives Prestigious American Society of Addiction Medicine Award
Lecture to focus on pharmacogenic treatment personalization for alcohol use disorder
CHARLOTTESVILLE, VA / ACCESSWIRE / April 4, 2019 / Adial Pharmaceuticals Inc., (NADSAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced that its Chief Medical Officer, Bankole Johnson, M.D., will be delivering the keynote lecture at the 50th Annual American Society of Addiction Medicine Conference on April 5th in Orlando, Florida. The subject of Dr. Johnson's address will be ''Personalizing the Treatment of Alcohol Use Disorders.''
At the Conference, Dr. Johnson is also being recognized as ASAM's 2019 recipient of the R. Brinkley Smithers Distinguished Scientist Award.
Dr. Johnson's lecture, slides and a brief summary will be available at a link on the Adial website in approximately one week. The presentation will focus on the premise that alcohol use disorder is a biological disorder with a moderate-to-high heritability with a goal of finding, ''the right medicine, for the right patient, at the right time, and for the right duration,'' according to Dr. Johnson. ''We know there are genomic biomarkers in the genotype that are promising indicators of drinking severity. Tailoring pharmacological agents for the subgroups of alcoholics based on their genetic variation may considerably improve treatment,'' said Dr. Johnson.
The R. Brinkley Smithers Distinguished Scientist Award recognizes and honors an individual who has made meritorious contributions in advancing the understanding of alcoholism, its prevention and treatment. The Award and Lecture were established by ASAM in 1995 as a lasting tribute to R. Brinkley Smithers, who influenced American alcoholism policy, theory and treatment.
''Dr. Johnson is certainly worthy of this recognition from his peers and his lecture will be demonstrative of his leadership in the critical efforts underway to address alcohol use disorder through clinically-based solutions, which is our focus at Adial,'' said William Stilley, CEO of Adial Pharmaceuticals. ''With Dr. Johnson's close involvement as our Chief Medical Officer, we are well-positioned to advance our pharmacological research around AD04. Given the great respect Dr. Johnson has earned within the profession, we believe the eyes of the world will be on our work and progress.''
The ASAM, founded in 1954, is a professional medical society representing more than 6,000 physicians, clinicians and associated professionals in the field of addiction medicine.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug candidate, AD04, is a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (''AUD''). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.
Forward Looking Statements
This communication contains certain ''forward-looking statements'' within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words ''believes,'' ''expects,'' ''anticipates,'' ''intends,'' ''projects,'' ''estimates,'' ''plans'' and similar expressions or future or conditional verbs such as ''will,'' ''should,'' ''would,'' ''may'' and ''could'' are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements are based upon current beliefs, expectations and assumptions and include statements regarding tailoring pharmacological agents for the subgroups of alcoholics based on their genetic variation being able to considerably improve treatment, being well-positioned to advance our pharmacological research around AD04, the eyes of the world being on our work and progress, plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to considerably improve treatment for the subgroups of alcoholics by tailoring pharmacological agents based on their genetic variation, our ability to advance our pharmacological research around AD04, our ability to commence the Phase 3 clinical trials in the first half of 2019, the ability of AD04 therapy to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2018. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Crescendo Communications, LLC
David Waldman / Natalya Rudman
SOURCE: Adial Pharmaceuticals Inc.
Released April 4, 2019